Cytodyn Inc. CEO Nader Pourhassan told BioWorld Today that his firm's advance into phase III trials with a self-injectable biologic for HIV bought several years ago from Progenics Pharmaceuticals Inc. may augur an era of not only vastly safer but more effective therapy, much less frequently dosed.